A Structured Benefit-Risk Assessment Operating Model for Investigational Medicinal Products in the Pharmaceutical Industry

Robust and transparent formal benefit-risk (BR) analyses for medicinal products represent a means to better understand the appropriate use of medicinal products, and to maximize their value to prescribers and patients. Despite regulatory and social imperatives to conduct structured BR (sBR) assessme...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Tim, Zorenyi, Gyorgy, Feron, Jane, Smith, Meredith, Nord, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276786/
https://www.ncbi.nlm.nih.gov/pubmed/37005972
http://dx.doi.org/10.1007/s43441-023-00508-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276786/
https://www.ncbi.nlm.nih.gov/pubmed/37005972
http://dx.doi.org/10.1007/s43441-023-00508-2

Ejemplares similares